her compounded semaglutide Hims? Hers? It's Novo Nordisk's Market Now Compounded GLP-1 - Semaglutide &

Description

A feature is that one dose of medication is injected just by pressing a button, eliminating the need to set the dosage or handle injection needles

Eating disorders

This can temporarily raise liver enzymes, which is usually a sign that liver fat is reducing rather than a cause for concern

Regional Insights North America GLP-1 Receptor Agonist Market Insights North America dominated the global GLP-1 Receptor Agonist Market in 2025 with approximately 45% of global revenues, anchored entirely by the United States' unique drug pricing environment and the commercial investment that Novo Nordisk and Eli Lilly have made in building GLP-1 prescribing across endocrinology, primary care, cardiology, and bariatric medicine